SFRP1 and triple-negative breast carcinoma: To our knowledge, the relationship between miR-105 and cisplatin-resistance has only been explored in triple-negative breast cancer (TNBC), where it was shown to activate Wnt/β-catenin signaling by downregulating SFRP1 and thereby promote chemoresistance in TNBC [18].